Post-IPO Debt - Santhera Pharmaceuticals
Investment Firm
Overview
Santhera Pharmaceuticals develops and markets pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases.
Announced Date
Jun 18, 2024
Funding Type
Post Ipo Debt
Highlights
Location
Switzerland, Europe
Social
Investor Lead
N/A
Participant Investors
1
| Investor Name |
|---|
 Highbridge Capital Management |
Round Details and Background
Santhera Pharmaceuticals raised $77583793 on 2024-06-18 in Post-IPO Debt
Santhera Pharmaceuticals develops and markets pharmaceutical products for the treatment of mitochondrial and neuromuscular diseases.
Company Funding History
12
| Announcment Date | Transaction Name | Number Of Investors | Lead Investor | Money Raised |
|---|---|---|---|---|
| Jun 18, 2024 |  Post-IPO Debt - Santhera Pharmaceuticals | 2 | - | 77.6M |
| Dec 17, 2004 | Series A - Santhera Pharmaceuticals | 2 | - | 18.6M |
| Aug 15, 2014 | Post-IPO Equity - Santhera Pharmaceuticals | - | 14.8M | |
| Oct 30, 2013 | Post-IPO Equity - Santhera Pharmaceuticals | 1 | - | 11.1M |
Recent Activity
There is no recent news or activity for this profile.